Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: A 30-year follow-up study of 740 incident patients with Type 2 diabetes

Diabetic Medicine

Volumn 30, Issue 3, 2013, Pages 349-357

  Jansson, S P O ^a,b   Andersson, D K G ^b   Svardsudd K ^b  

^a ÖREBRO UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE;

EID: 84874187915     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12106     Document Type: Article

References (29)

1. Solomon CG. Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 2003; 348: 457-459.
2. Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544-1550.
3. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 2007; 28: 3059-3066.
4. Mourad JJ, Le Jeune S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl 2008; 26: S7-S13.
5. Sehestedt T, Hansen TW, Li Y, Richart T, Boggia J, Kikuya M et al. Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertens Res 2011; 34: 714-721.
6. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
7. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
10. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. l
11. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N Engl J Med 2009; 360: 129-139.
12. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
13. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al. Intensive glucose control and macrovascular outcomes in Type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
14. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678.
15. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in Type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
16. Andersson DK, Lundblad E, Svärdsudd K. A model for early diagnosis of Type 2 diabetes mellitus in primary health care. Diabet Med 1993; 10: 167-173.
17. Jansson SP, Andersson DK, Svärdsudd K. Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up. Diabetologia 2007; 50: 703-710.
18. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A et al. Risk of cardiovascular disease and all cause mortality among patients with Type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
19. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
20. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
21. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012; 172: 1296-1303.
22. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769.
23. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
24. (1990) UK Prospective Diabetes Study 6. Complications in newly diagnosed Type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13: 1-11.
25. Hansen LJ, Olivarius Nde F, Siersma V. 16-year excess all-cause mortality of newly diagnosed Type 2 diabetic patients: a cohort study. BMC Public Health 2009; 9: 400.
26. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007; 30: 1241-1247.
27. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
28. Jansson SP, Andersson DK, Svärdsudd K. Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care 2010; 33: 551-556.
29. Ware JH, Hamel MB. Pragmatic trials - guides to better patient care? N Engl J Med 2011; 364: 1685-1687.